$VBIV For newbies here; GSK Engerix-B generated about $800MIL/per year, but the patent soon will expire and will be available as a generic. If I were GSK, do I want to share my lucrative lunch with another player or keep it for myself? I believe M&A talk has been DONE already and was waiting for the data and 6 months grace period for the insiders who bought boatloads of shares back in September. CONSTANT data is out and showed superiority over EngerixB. Sci-B Vac is the 3rd GENERATION VACCINE which will take $2.6 Bil market worldwide by 2024. Upside risk is much greater with BO thesis now much stronger than ever than downside from here. Bottom line: HOLD TIGHT and KEEP ACCUMULATE as much as you can!!!
  • 9
  • 12